Related Experiment Video
Updated: Aug 25, 2025

04:11
Author Spotlight: Advancements and Challenges in Hepatitis B Virus Detection
Published on: December 15, 2023
3.7K
SNROW-based highly sensitive label-free surface biosensor for hepatitis B detection
Applied Optics
|October 18, 2022
Summary
A novel silicon nanowire optical waveguide sensor can detect Hepatitis B surface antigen (HBsAg) with ultra-high sensitivity. This label-free biosensor offers early hepatitis B detection, crucial for timely treatment and preventing liver damage.
Area of Science:
- Nanotechnology
- Biomedical Engineering
- Optical Sensing
Background:
- Hepatitis B virus (HBV) remains a global health issue despite available vaccines.
- Early detection of HBV is critical to prevent disease progression and liver damage.
- Current detection methods may lack the sensitivity for very early-stage diagnosis.
Purpose of the Study:
- To theoretically demonstrate a silicon nanowire optical waveguide for label-free detection of Hepatitis B surface antigen (HBsAg).
- To optimize the waveguide design for enhanced light-analyte interaction and high sensitivity.
- To evaluate the sensor's performance, including its detection limit and sensitivity for HBsAg.
Main Methods:
- Theoretical simulation using finite-element method-based COMSOL Multiphysics.
- Design and optimization of a silicon nanowire rectangular optical waveguide.
- Mimicking biomarker detection segments as adlayers on the waveguide surface.
- Incorporating the waveguide into a Mach-Zehnder interferometer (MZI) for enhanced sensing.
Main Results:
- Achieved ultra-high surface sensitivities: 7.03×2π rad/nm (phase) and 3421.89 µW/nm (MZI).
- Demonstrated an excellent detection limit of 2.92×10⁻³ pg/mm² for HBsAg.
- The sensor can measure HBsAg concentrations as low as 0.00973 ng/mL, enabling early-stage detection.
Conclusions:
- The proposed silicon nanowire optical waveguide sensor offers a highly sensitive and label-free method for HBsAg detection.
- This technology has the potential for early diagnosis of hepatitis B infection.
- The device's sensitivity surpasses requirements for early-stage detection, aiding timely therapeutic intervention.

